Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Association between Acute Declines in eGFR during Renin-Angiotensin System Inhibition and Risk of Adverse Outcomes

Open access

Abstract

Key Points: Renin-angiotensin system inhibition was favorable for risk of kidney failure (compared with 0% decline with use of placebo or other agents) up to declines in eGFR of 13% over a 3-month period. Relation between eGFR decline after renin-angiotensin system inhibitor initiation and risk of outcomes was stronger in the first 2 years of follow-up and waned over time. Background: Declines in GFR occur commonly when renin-angiotensin system (RAS) inhibitors are started. Our objective was to determine the relation between declines in eGFR during trials of RAS inhibition and kidney outcomes. Methods: We included participants with CKD (eGFR <60 ml/min per 1.73 m 2 ) from 17 trials of RAS inhibition. The exposure was subacute declines in eGFR expressed as % change between randomization and month 3, and in the subset of trials with data available, we also examined % change in eGFR between randomization and month 1. The primary outcome was kidney failure with replacement therapy. Cox proportional hazards models were used to examine the association between subacute declines in eGFR and risk of kidney failure. We used spline models to identify the threshold of change in eGFR below which RAS inhibition was favorable (conservatively comparing a given decline in eGFR with RAS inhibition to no decline in the comparator). Results: A total of 11,800 individuals with mean eGFR 43 (SD 11) ml/min per 1.73 m 2 and median urine albumin-to-creatinine ratio of 362 mg/g (interquartile range, 50–1367) were included, and 1162 (10%) developed kidney failure. The threshold of decline in eGFR that favored the use of RAS inhibitors for kidney failure was estimated to be up to 13% (95% confidence interval, 8% to 17%) over a 3-month interval and up to 21% (95% confidence interval, 15% to 27%) over a 1-month interval after starting RAS inhibitors. Conclusions: In patients treated with RAS inhibitors, ≤13% decline in eGFR over a 3-month period or ≤21% decline over a 1-month period was associated with lower risk of kidney failure compared with no decline in those assigned to placebo or other agents.

Overview

Integrity signals

Registry

Crossref · 10.1681/asn.0000000000000426

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 39 references

Cited by

See all 26

Metadata

Authors
Ku, E., Tighiouart, H., McCulloch, C. E., Inker, L. A., Adingwupu, O. M., Greene, T., Estacio, R. O., Woodward, M., de Zeeuw, D., Lewis, J. B., Hannedouche, T., Hou, F. F., Jafar, T. H., Imai, E., Remuzzi, G., Heerspink, H. J. L., Toto, R. D., & Sarnak, M. J.
Affiliations
  • University of California, San Francisco (US)
  • Tufts University (US)
  • Tufts Medical Center (US)
  • University of Utah (US)
  • Denver Health Medical Center (US)
  • The George Institute for Global Health (GB)
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
  • University Medical Center Groningen (NL)
Venue
Journal of the American Society of Nephrology
Published
2024-06-18
Volume
35
Issue
10
Pages
1402-1411
ISSN
  • 1046-6673 (ISSN-L)
  • 1533-3450
OpenAlex
W4399767475
Cited by
24
References
39
Citations by year
2026: 7 · 2025: 14 · 2024: 3
FWCI
6.80
Type
journal article
Language
en
Open access
Locations
  • Journal of the American Society of Nephrology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
Funders
Foundation for the National Institutes of Health (R01 DK121904)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
renin-angiotensin system inhibitors, estimated glomerular filtration rate decline, chronic kidney disease, renal failure, adverse outcomes, threshold analysis, albuminuria, dose-response relationship, ACE inhibitors, angiotensin receptor blockers, risk-benefit assessment
MeSH terms
Aged, Angiotensin-Converting Enzyme Inhibitors, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Renin-Angiotensin System, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association between Acute Declines in eGFR during Renin-Angiotensin System Inhibition and Risk of Adverse Outcomes. https://app.cochat.ai/papers/10.1681/asn.0000000000000426
The paper
Ku, E., Tighiouart, H., McCulloch, C. E., Inker, L. A., Adingwupu, O. M., Greene, T., Estacio, R. O., Woodward, M., de Zeeuw, D., Lewis, J. B., Hannedouche, T., Hou, F. F., Jafar, T. H., Imai, E., Remuzzi, G., Heerspink, H. J. L., Toto, R. D., & Sarnak, M. J. (2024). Association between Acute Declines in eGFR during Renin-Angiotensin System Inhibition and Risk of Adverse Outcomes. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000000000000426

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.